The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes.

Abstract:

:Acute monocytic leukemia (M5) is a subtype of acute myeloid leukemia (AML) with two distinct morphologic subcategories, M5a and M5b. We compared the immunophenotype, cytogenetics and clinical outcome of AML M5 with non-M5 AML and also compared M5a with M5b. One hundred and twelve M5 (76 M5a, 36 M5b) and 726 non-M5 cases were identified and treated on protocols at our institution. There were no significant differences in immunophenotype between M5a and M5b. Translocation 11q23 was the sole abnormality in 18.6% of M5 and 3.2% of non-M5 (p<0.001). Trisomy 8 was also more prevalent in M5 (16.9%) than in non-M5 (8.7%; p=0.03). There was no significant difference in karyotypes between M5a and M5b. The complete remission rate was 70% for AML M5 and 57% for non-M5 AML (p=0.03). There was no significant difference in median overall survival or disease free survival for patients with M5 versus non-M5, M5a versus M5b. Our data indicate that the prognosis of AML M5 is similar to non-M5 AML and that M5a and M5b do not differ in immunophenotype, cytogenetics or clinical outcome.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Villeneuve P,Kim DT,Xu W,Brandwein J,Chang H

doi

10.1016/j.leukres.2007.06.019

subject

Has Abstract

pub_date

2008-02-01 00:00:00

pages

269-73

issue

2

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(07)00252-4

journal_volume

32

pub_type

杂志文章
  • Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.

    abstract:BACKGROUND:Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. F...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.01.002

    authors: Xiao D,Shi Y,Fu C,Jia J,Pan Y,Jiang Y,Chen L,Liu S,Zhou W,Zhou J,Tao Y

    更新日期:2016-03-01 00:00:00

  • Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide.

    abstract::We hypothesized that the lipid second messenger, ceramide, and microtubule-directed chemotherapeutic agents might engage converging pathways in inducing apoptosis. Our studies demonstrated that simultaneous treatment of Jurkat cells with paclitaxel and ceramide enhanced paclitaxel-induced cell growth inhibition. Cell ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(99)00048-x

    authors: Myrick D,Blackinton D,Klostergaard J,Kouttab N,Maizel A,Wanebo H,Mehta S

    更新日期:1999-06-01 00:00:00

  • WITHDRAWN: The effect of dihydroartemisinin on TfR and VEGF expression in iron overload human myeloid leukemia K562 cells.

    abstract::This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.01.006

    authors: Zengwang,Zhou HJ,Li A,Zhang JL

    更新日期:2009-02-20 00:00:00

  • Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.

    abstract:BACKGROUND:Current results regarding treatment outcomes in acute myeloid leukemia (AML) point to significant differences between low- and middle-income countries (LMIC) and high-income countries (HIC). Excluding well-known socioeconomic issues, genetic markers important for prognosis have not been properly incorporated...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2017.07.005

    authors: Benicio MTL,Ribeiro AFT,Américo AD,Furtado FM,Glória AB,Lima AS,Santos SM,Xavier SG,Lucena-Araujo AR,Fagundes EM,Rego EM

    更新日期:2017-09-01 00:00:00

  • The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

    abstract::HSP90 is a multi-client chaperone involved in regulating a large array of cellular processes and is commonly overexpressed in many different cancer types including hematological malignancies. Inhibition of HSP90 holds promise for targeting multiple molecular abnormalities and is therefore an attractive target for hete...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.03.016

    authors: Lazenby M,Hills R,Burnett AK,Zabkiewicz J

    更新日期:2015-06-01 00:00:00

  • Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.

    abstract::Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Co...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2019.02.009

    authors: King AC,Pappacena JJ,Tallman MS,Park JH,Geyer MB

    更新日期:2019-04-01 00:00:00

  • Aetiologic factors in lymphoid malignancies: a case-control epidemiological study.

    abstract::A prospective case-control study of the aetiologic factors involved in the production of lymphoid malignancies has been conducted within a defined geographical area covering six health districts in the Yorkshire Region. Among the aspects investigated were past medical events, occupations and certain social factors. A ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90016-x

    authors: Bernard SM,Cartwright RA,Bird CC,Richards ID,Lauder I,Roberts BE

    更新日期:1984-01-01 00:00:00

  • Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.

    abstract::The MYBL2 gene encodes a transcription factor implicated in cell proliferation and maturation whose amplification or overexpression has been associated with different human malignancies, suggesting that it could be implicated in tumorigenesis. We analyzed MYBL2 expression and its prognostic value in 291 patients with ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.09.015

    authors: Fuster O,Llop M,Dolz S,García P,Such E,Ibáñez M,Luna I,Gómez I,López M,Cervera J,Montesinos P,Moscardó F,Cordón L,Solves P,de Juan I,Palanca S,Bolufer P,Sanz MÁ,Barragán E

    更新日期:2013-12-01 00:00:00

  • BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

    abstract::The Bcl-2 protein inhibits apoptosis (programmed cell death) of hematopoietic stem cells induced by a variety of noxious stimuli, thus mediating chemoresistance and decreasing chemosensitivity. Higher Bcl-2 expression correlates to an adverse outcome following therapy for acute myeloid leukemia (AML). The current stud...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.05.009

    authors: Moon JH,Sohn SK,Lee MH,Jang JH,Kim K,Jung CW,Kim DH

    更新日期:2010-02-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract::We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(97)00135-5

    authors: Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期:1998-01-01 00:00:00

  • Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia.

    abstract::Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge. Numerous clinical trials have failed to identify new treatments or combinations of existing therapies that substantially improve outcomes and s...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2016.05.025

    authors: Kell J

    更新日期:2016-08-01 00:00:00

  • Molecular characterization and prognostic significance of FLT3 in CML progression.

    abstract::To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.11.008

    authors: Kim KI,Park J,Ahn KS,Won NH,Kim BK,Shin WG,Yoon SS,Oh JM

    更新日期:2010-08-01 00:00:00

  • Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.

    abstract::Compound 48 (C48) is a novel dual ligand for peroxisome proliferator-activated receptor alpha and gamma (PPAR alpha/gamma). Culture of imatinib-sensitive and -resistant CML cell lines with C48 resulted in a strong growth inhibition which associated with G0/G1 cell cycle arrest. However, it showed no obvious toxicity t...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.11.023

    authors: Bertz J,Zang C,Liu H,Wächter M,Possinger K,Koeffler HP,Elstner E

    更新日期:2009-05-01 00:00:00

  • Mixed myelodysplastic and myeloproliferative syndromes.

    abstract::Aplastic anemia, myelodysplastic syndromes (MDS) and chronic myeloproliferative diseases (MPD) are stem cell disorders. There is no clear-cut demarcation of them. Hypoplastic MDS displays features of aplastic anemia and MDS, on the other side mixed myelodysplastic and myeloproliferative syndromes (MDS-MPS) develop. In...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/0145-2126(96)00028-8

    authors: Neuwirtová R,Mociková K,Musilová J,Jelínek J,Havlícek F,Michalová K,Adamkov M

    更新日期:1996-09-01 00:00:00

  • Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

    abstract::Fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGF beta R and NPM/ALK arise from reciprocal chromosomal translocations and cause acute and chronic myelogenous leukemias and non-Hodgkin's lymphoma. Murine hematopoietic growth factor dependent BaF3 cells and cells transformed by FTK (BaF3-FTK) w...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00163-7

    authors: Hoser G,Majsterek I,Romana DL,Slupianek A,Blasiak J,Skorski T

    更新日期:2003-03-01 00:00:00

  • Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.

    abstract::Accumulation of cytosine arabinoside triphosphate (araCTP) from a range of cytosine arabinoside (araC) concentrations (1-50 microM) was measured during incubations of leukemic cells freshly isolated from patients with acute leukemia. In all but one patient, increments in extracellular araC above 10 microM did not incr...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(90)90035-8

    authors: Jamieson GP,Snook MB,Wiley JS

    更新日期:1990-01-01 00:00:00

  • Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid.

    abstract::All-trans-retinoic acid (ATRA) has been proven active against a range of malignancies in isolated tissue culture systems and in human clinical trials, but the duration of its effects has been transient. Recent evidence indicates that the basis for the limited duration of ATRA's activity, at least in one form of leukem...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90040-x

    authors: Mehta K,Sadeghi T,McQueen T,Lopez-Berestein G

    更新日期:1994-08-01 00:00:00

  • Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia.

    abstract::The simultaneous occurrence of two specific acquired chromosomal abnormalities in chronic or acute leukaemias is rare. Inherited chromosomal abnormalities are also rare events in the general population. In chronic myeloid leukaemia (CML), characterised by the t(9;22)(q34;q11), the inv(16)(p13q22) has been described as...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.06.003

    authors: Silva PM,Lourenço GJ,Bognone RA,Delamain MT,Pinto-Junior W,Lima CS

    更新日期:2006-01-01 00:00:00

  • Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.

    abstract::A retrospective analysis of the relationship between the initial classification according to either FAB or WHO criteria, the presence of risk factors and the type of therapy including stem cell transplantation (SCT) on the survival was performed in a group of 106 patients with primary myelodysplastic syndrome (MDS) of...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2003.10.016

    authors: Cermák J,Vítek A,Michalová K

    更新日期:2004-06-01 00:00:00

  • The clonogenic potential of selected CD34+ cells from patients with MDS appear preserved when tested ex vivo.

    abstract::Our aim was to examine in 17 patients with MDS the effects of PMA activated and non-activated autologous lymphocytes on selected bone marrow CD34+ progenitors, in dose response studies. We used a double layer culture technique. Compared with controls, there was no difference in the colony growth promoting capacity of ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.03.017

    authors: Davison GM,Novitzky N,Abdulla R

    更新日期:2011-09-01 00:00:00

  • Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis.

    abstract::Chronic B-lymphocytic leukemia (B-CLL) cells may be regulated by immune functions. In an attempt to analyze such functions, helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8) and sIL-2R and beta 2-microglobulin were measured in serum of patients at different stages of the disease. Patient...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(92)90009-v

    authors: Aguilar-Santelises M,Loftenius A,Ljungh C,Svenson SB,Andersson B,Mellstedt H,Jondal M

    更新日期:1992-06-01 00:00:00

  • Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.

    abstract::Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristin...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.08.016

    authors: Miyashita K,Tomita N,Taguri M,Suzuki T,Ishiyama Y,Ishii Y,Nakajima Y,Numata A,Hattori Y,Yamamoto W,Miyazaki T,Tachibana T,Takasaki H,Matsumoto K,Hashimoto C,Takemura S,Yamazaki E,Fujimaki K,Sakai R,Motomura S,Ishi

    更新日期:2015-08-29 00:00:00

  • Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

    abstract::The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transpl...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2013.10.013

    authors: Neukirchen J,Lauseker M,Blum S,Giagounidis A,Lübbert M,Martino S,Siragusa S,Schlenk RF,Platzbecker U,Hofmann WK,Götze K,Palumbo GA,Magrin S,Kündgen A,Aul C,Hildebrandt B,Hasford J,Kobbe G,Haas R,Germing U

    更新日期:2014-01-01 00:00:00

  • Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea.

    abstract::We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS). Retrospective analysis of a cryoprese...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00140-0

    authors: Flamm MJ,Murty VV,Rao PH,Nichols GL

    更新日期:2002-04-01 00:00:00

  • Ploidy status rarely changes in myeloma patients at disease progression.

    abstract::Hyperdiploid and non-hyperdiploid multiple myeloma represents distinct biological entities characterized by different patterns of genetic changes. We sought to determine whether ploidy category (non-hyperdiploid versus hyperdiploid) remains stable over time from diagnosis to progression. Of the 43 patients studied (39...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2005.07.004

    authors: Chng WJ,Winkler JM,Greipp PR,Jalal SM,Bergsagel PL,Chesi M,Trendle MC,Ahmann GJ,Henderson K,Blood E,Oken MM,Hulbert A,Van Wier SA,Santana-Dávila R,Kyle RA,Gertz MA,Lacy MQ,Dispenzieri A,Fonseca R

    更新日期:2006-03-01 00:00:00

  • Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.

    abstract::In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins. Lung resistance-related protein (LRP), multidrug resistance-associated protein and P-glycoprotein are three MD...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.10.012

    authors: Yasunami T,Wang YH,Tsuji K,Takanashi M,Yamada Y,Motoji T

    更新日期:2007-04-01 00:00:00

  • Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele.

    abstract::Predisposition to lymphomagenesis is a well-known phenomenon of ataxia-telangiectasia, a recessive disorder caused by germline inactivation of ATM. ATM encodes a protein implicated in the repair of radiation induced double-strand breaks. Biallelic ATM inactivation was described also in sporadic lymphoid malignancies, ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.11.010

    authors: Briani C,Schlotter M,Lichter P,Kalla C

    更新日期:2006-09-01 00:00:00

  • Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.

    abstract::The treatment of acute leukemia is still challenging due in part to the development of resistance and relapse. This chemotherapeutics resistance is established by clonal selection of resistant variants of the cancer cells. Recently, a horizontal transfer of chemo-resistance among cancer cells via extracellular vesicle...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.09.014

    authors: Bouvy C,Wannez A,Laloy J,Chatelain C,Dogné JM

    更新日期:2017-11-01 00:00:00

  • Complete variable region deletion in a mu heavy chain disease protein (ROUL). Correlation with light chain secretion.

    abstract::In a patient affected with chronic lymphocytic leukemia with lymphocyte surface mu and kappa determinants and vacuolated bone marrow plasma cells, the serum contained polymers of a truncated mu chain and normal-sized kappa chains. These light chains were present as monomers and covalent dimers in studies performed und...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90129-9

    authors: Cogné M,Aucouturier P,Brizard A,Dreyfus B,Duarte F,Preud'homme JL

    更新日期:1993-06-01 00:00:00

  • Multiple centrosomal microtubule organising centres and increased microtubule stability are early features of VP-16-induced apoptosis in CCRF-CEM cells.

    abstract::Microtubular reorganisation contributing to apoptotic morphology occurs in normal and neoplastic cells undergoing apoptosis induced by cytotoxic drugs [1-3]. The aim of this study was to correlate the changes in the microtubules (MTs) with behavior of the centrosome in apoptotic cells, and to see whether post-translat...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(97)00038-6

    authors: Pittman S,Geyp M,Fraser M,Ellem K,Peaston A,Ireland C

    更新日期:1997-06-01 00:00:00